Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Wintao Communications
301139
5
WuHan Hvsen Biotechnology
300871
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Operating revenue | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 |
Cost of revenue | ||||||||||
Gross profit | ||||||||||
Operating expense | 33.94%58.87M | 57.99%16.44M | 57.40%17.07M | 31.32%14.07M | -5.82%11.29M | 16.56%43.95M | -23.21%10.41M | 26.30%10.85M | 37.66%10.71M | 53.95%11.99M |
Selling and administrative expenses | 11.92%22.37M | 31.54%5.9M | 17.47%5.73M | 5.62%5.68M | -3.56%5.06M | 50.29%19.99M | 4.52%4.49M | 27.33%4.88M | 49.19%5.37M | 233.40%5.25M |
-General and administrative expense | 11.92%22.37M | 31.54%5.9M | 17.47%5.73M | 5.62%5.68M | -3.56%5.06M | 50.29%19.99M | 4.52%4.49M | 27.33%4.88M | 49.19%5.37M | 233.40%5.25M |
Research and development costs | 52.31%36.5M | 78.05%10.54M | 90.03%11.34M | 57.19%8.39M | -7.58%6.23M | -1.82%23.96M | -36.07%5.92M | 25.48%5.97M | 27.72%5.34M | 8.45%6.74M |
Operating profit | -33.94%-58.87M | -57.99%-16.44M | -57.40%-17.07M | -31.32%-14.07M | 5.82%-11.29M | -16.56%-43.95M | 23.21%-10.41M | -26.30%-10.85M | -37.66%-10.71M | -53.95%-11.99M |
Net non-operating interest income expense | 2.30%13.41M | -6.74%3.33M | -5.53%3.28M | 6.52%3.36M | 18.18%3.43M | 413.03%13.11M | 73.38%3.58M | 806.01%3.47M | 2,851.40%3.16M | 2.91M |
Non-operating interest income | 2.30%13.41M | -6.74%3.33M | -5.53%3.28M | 6.52%3.36M | 18.18%3.43M | 413.03%13.11M | 73.38%3.58M | 806.01%3.47M | 2,851.40%3.16M | --2.91M |
Other net income (expense) | -127.27%-6K | 66.67%-2K | -111.76%-4K | 75.00%-1K | 150.00%1K | 1,200.00%22K | -6K | 34K | -4K | -166.67%-2K |
Other non- operating income (expenses) | -127.27%-6K | 66.67%-2K | -111.76%-4K | 75.00%-1K | 150.00%1K | 1,200.00%22K | ---6K | --34K | ---4K | -166.67%-2K |
Income before tax | -47.51%-45.47M | -91.73%-13.11M | -87.92%-13.8M | -41.63%-10.71M | 13.53%-7.86M | 12.32%-30.82M | 40.50%-6.84M | 10.51%-7.34M | 1.51%-7.56M | -16.71%-9.09M |
Income tax | ||||||||||
Net income | -47.51%-45.47M | -91.73%-13.11M | -87.92%-13.8M | -41.63%-10.71M | 13.53%-7.86M | 12.32%-30.82M | 40.50%-6.84M | 10.51%-7.34M | 1.51%-7.56M | -16.71%-9.09M |
Net income continuous Operations | -47.51%-45.47M | -91.73%-13.11M | -87.92%-13.8M | -41.63%-10.71M | 13.53%-7.86M | 12.32%-30.82M | 40.50%-6.84M | 10.51%-7.34M | 1.51%-7.56M | -16.71%-9.09M |
Minority interest income | ||||||||||
Net income attributable to the parent company | -47.51%-45.47M | -91.73%-13.11M | -87.92%-13.8M | -41.63%-10.71M | 13.53%-7.86M | 12.32%-30.82M | 40.50%-6.84M | 10.51%-7.34M | 1.51%-7.56M | -16.71%-9.09M |
Preferred stock dividends | ||||||||||
Other preferred stock dividends | ||||||||||
Net income attributable to common stockholders | -47.51%-45.47M | -91.73%-13.11M | -87.92%-13.8M | -41.63%-10.71M | 13.53%-7.86M | 12.32%-30.82M | 40.50%-6.84M | 10.51%-7.34M | 1.51%-7.56M | -16.71%-9.09M |
Basic earnings per share | -39.74%-1.09 | -70.59%-0.29 | -73.68%-0.33 | -36.84%-0.26 | 13.04%-0.2 | 68.16%-0.78 | 41.74%-0.17 | 78.89%-0.19 | 8.93%-0.19 | -8.72%-0.23 |
Diluted earnings per share | -39.74%-1.09 | -70.59%-0.29 | -73.68%-0.33 | -36.84%-0.26 | 13.04%-0.2 | 68.16%-0.78 | 41.74%-0.17 | 78.89%-0.19 | 8.93%-0.19 | -8.72%-0.23 |
Dividend per share | ||||||||||
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | -- | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |